UnitedHealthcare Pharmacy
Clinical Pharmacy Programs
Program Number 2025 P 1412-3
Program Prior Authorization/Notification
Medication Skyclarys® (omaveloxolone)
P&T Approval Date 5/2023, 5/2024, 5/2025
Effective Date 8/1/2025
1. Background:
Skyclarys (omaveloxolone) is indicated for the treatment of Friedreich’s ataxia in adults and
adolescents aged 16 years and older.
2. Coverage Criteriaa:
A. Initial Authorization
1. Skyclarys will be approved based on the following criterion:
a. Diagnosis of Friedreich’s ataxia
Authorization will be issued for 12 months.
B. Reauthorization
1. Skyclarys will be approved based on the following criterion:
a. Documentation of positive clinical response to Skyclarys therapy
Authorization will be issued for 12 months.
a State mandates may apply. Any federal regulatory requirements and the member specific
benefit plan coverage may also impact coverage criteria. Other policies and utilization
management programs may apply.
3. Additional Clinical Rules:
• Notwithstanding Coverage Criteria, UnitedHealthcare may approve initial and re-
authorization based solely on previous claim/medication history, diagnosis codes (ICD-
10) and/or claim logic. Use of automated approval and re-approval processes varies by
program and/or therapeutic class.
• Supply limits and/or Medical Necessity may be in place.
4. References:
1. Skyclarys™ [package insert]. Plano, TX: Reata Pharmaceuticals, Inc.; December 2024.
© 2025 UnitedHealthcare Services, Inc.
1
Program Prior Authorization/Notification - Skyclarys™ (omaveloxolone)
Change Control
5/2023 New program.
5/2024 Annual review with no changes to coverage criteria. Updated
references.
5/2025 Annual review with no changes to coverage criteria. Updated
references.
© 2025 UnitedHealthcare Services, Inc.
2